Clinical trial · Observational
Comparison of Geriatric Screening Methods in Newly Diagnosed Multiple Myeloma Patients
Comparison of Different Geriatric Screening Methods in Newly Diagnosed Multiple Myeloma Patients, and Assessment of Therapeutic Efficacy and Toxicity in Fit and Frail Patients. A Multicenter Observational Belgian Study.
NCT02918695CI-TRIAL-00051594COMPASScompletedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The purpose of this study is to compare clinical judgment and comprehensive geriatric assessment as screening tools for optimization of treatment for newly diagnosed elderly multiple myeloma patients.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Hematologic Diseases | — | UNRESOLVED | — |
| Multiple Myeloma | Multiple Myeloma | CURATED_EXACT | 0.92 |
Interventions
Interventions (0)
Data not yet available
No intervention recorded.
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (1)
- measure
- Comparison of the geriatric categorization (fit versus frail) by standard clinical assessment versus by geriatric scoring.
- timeFrame
- At baseline
- description
- Comparison of geriatric categorization by standard clinical assessment (fit versus frail ) versus by geriatric scoring ( G8 score, CGA (Comprehensive Geriatric Assessment) and IMWG score will result in fit or frail) will be presented in proportion of agreement (accuracy, specificity, sensitivity, positive predictive value, negative predictive value).
Secondary outcomes (12)
- measure
- Comparison of the geriatric categorization (fit versus frail) by CGA versus by IMWG scoring
- timeFrame
- At baseline
- description
- The results will be presented in terms of accuracy, specificity, sensitivity, positive predictive value, negative predictive value.
- measure
- Change in geriatric categorization (fit versus frail) by CGA from baseline to 3 months of anti-myeloma therapy.
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 70 Years
Show eligibility criteria text
Inclusion Criteria: * newly diagnosed multiple myeloma * age =\> 70 years * no previous anti-myeloma treatment except for local radiotherapy or short course (max 4 days) of high-dose dexamethasone * signed informed consent * patients included in an interventional therapeutic trial are eligible Exclusion Criteria: * previous systemic anti-myeloma treatment * severe mental or cognitive disorder precluding geriatric assessment * patient refusal to sign informed consent
References
Publications (0)
Data not yet available
No reference posted for this study.